{"filings":[{"id":788160,"accession_number":"0001493152-26-026773","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-06-02T12:30:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity SAB webinar on CyPath Lung for early lung cancer detection on June 16","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Society for Advanced Bronchoscopy hosts free webinar June 16, 7pm ET on CyPath Lung's role in early lung cancer detection.","Panel includes med onc Vijay Gunuganti, thoracic surgeon Reginald Baptiste, interventional pulmonologist Sai Guda.","CyPath Lung is a noninvasive sputum test using flow cytometry and AI; published trial: 92% sensitivity, 87% specificity, 99% NPV for nodules <20mm.","Webinar to discuss real-world benefits: guiding surgery, reducing unnecessary procedures, supporting surveillance.","CEO Maria Zannes notes collaboration with SAB to advance minimally invasive lung diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677999,"accession_number":"0001493152-26-025338","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-05-27T12:30:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces Mexican patent allowance for CyPath Lung cancer detection method","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mexican patent allowance for flow-cytometry methods to detect lung cancer using CyPath Lung.","Patent will protect use of defined antibodies and TCPP porphyrin to label sputum cells.","CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in trial.","IP portfolio now includes patents in US, EU, China, Japan, Australia, Canada, and Mexico."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":24001,"accession_number":"0001493152-26-022428","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-05-12T13:20:15+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.","Sales growth so far in 2026 exceeds internal projections, reflecting accelerating physician adoption.","CyPath Lung uses flow cytometry + AI for noninvasive lung cancer detection; 92% sensitivity, 87% specificity in trial.","Company advancing longitudinal clinical study, expanding use for lung cancer survivor monitoring, and R&D pipeline for asthma/COPD.","CEO Maria Zannes highlights CyPath Lung's role in risk stratification and nodule management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94923,"accession_number":"0001493152-26-021861","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.","Total revenue $1.4M, down 27% from $1.9M due to discontinuing unprofitable pathology services.","Net loss $3.6M ($0.81/share) vs $2.7M ($4.80/share) in Q1 2025; cash $3.1M.","Physician offices ordering CyPath Lung increased 69% YoY; company expects acceleration.","Launched DoD-funded longitudinal trial; Brooke Army Medical Center study for asthma/COPD companion tests."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":1351527.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94922,"accession_number":"0001493152-26-020591","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.","Plan amended to increase shares reserved under 2024 Plan from 66,666 to 1,000,000.","Approved warrant exercise of up to 271,500 shares and anti-dilution adjustments (floor $4.50 for warrants, $3.00 for Series B).","Six directors elected: Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Roberto Rios, John J. Oppenheimer.","Ratified WithumSmith+Brown as independent auditor for fiscal year 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94921,"accession_number":"0001493152-26-016486","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CyPath® Lung case study shows test helped defer biopsy for high-risk patient with 30mm nodule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["70-year-old female, 50 pack-year smoking history, 30mm lung nodule with high cancer risk by imaging and models.","CyPath® Lung returned negative result ('Unlikely Malignancy'); follow-up CT showed nodule had completely resolved.","Treating pulmonologist credited CyPath® Lung for prompting additional imaging before scheduled biopsy.","CyPath® Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in small nodules in clinical trial.","Case illustrates potential to avoid risky, unnecessary procedures in patients with comorbidities like emphysema."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94920,"accession_number":"0001493152-26-015445","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies' CyPath Lung featured at Cleveland Clinic symposium Apr 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung test to be highlighted at invitation-only 'Advances in Early Lung Cancer Detection' symposium.","CMO Gordon Downie, MD, PhD, to serve on panel discussing lung nodule management.","Test has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.","This marks the company's seventh invitation to present at the Cleveland Clinic symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94919,"accession_number":"0001493152-26-014653","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.","Full-year 2025 CyPath Lung revenue rose 87% YoY, units sold up 99% vs 2024.","Addressable U.S. market estimated at $3.58 billion; capturing 10% would represent $358M in sales.","Company advancing large-scale clinical study and R&D pipeline for asthma/COPD diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107640,"accession_number":"0001493152-26-012808","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"bioAffinity posts investor presentation on website; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation materials made available on company website on March 26, 2026.","The 8-K filing does not include specific operational or financial updates.","Tickers referenced: BIAF (common) and BIAFW (warrants).","No quantitative guidance or material events disclosed in the furnished exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107639,"accession_number":"0001493152-26-012683","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces virtual physician roundtable on CyPath® Lung for April 8, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Webinar titled 'CyPath® Lung in Practice: A Physician Roundtable Discussion' on April 8, 2026 at 7 p.m. ET.","Moderated by CMO Gordon H. Downie, MD, PhD; panel includes three pulmonologists sharing real-world cases.","CyPath® Lung achieved 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in high-risk patients with small nodules.","First of a series aimed at integrating noninvasive CyPath® Lung into pulmonary practice for nodule management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107638,"accession_number":"0001493152-26-010584","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity case study shows CyPath Lung avoided invasive biopsy in high-risk nodule patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["71-year-old former smoker with multiple lung nodules received CyPath Lung 'Unlikely Malignancy' result.","Physician delayed invasive biopsy based on test result; follow-up CT showed nodules resolved or stable.","CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy in clinical study for nodules <20mm.","Case study underscores noninvasive test's potential to reduce patient anxiety and lower healthcare costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107637,"accession_number":"0001493152-26-009986","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.","CyPath Lung revenue increased 87% YoY; tests performed up 99%, physician orders up 67%.","Net loss $14.9M vs $9.0M in 2024, driven by warrant fair value changes and higher commercialization costs.","Cash $6.5M at year-end; raised $16.9M in equity in 2025. Guidance: >100% CyPath Lung unit sales growth in 2026.","Appointed Gordon Downie MD PhD as CMO; Roberto Rios CPA and John Oppenheimer MD to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107636,"accession_number":"0001493152-26-009463","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.","Study will include up to 20 sites, including a dozen VA medical centers and two large military hospitals.","Earlier trial showed 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in nodules <20mm.","Enrollment expected up to 18 months; patients followed up to 24 months or until definitive diagnosis.","Murtha Cancer Center Research Program provides support and funding for federal facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107635,"accession_number":"0001493152-26-009154","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors not standing for re-election at bioAffinity Technologies' 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Anderson and Roby Joyce informed the board on March 5, 2026 of their decisions not to stand for re-election.","Their terms expire at the Annual Meeting currently scheduled for April 30, 2026.","The decisions did not result from any disagreements with the company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107634,"accession_number":"0001493152-26-008723","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity presents positive data on sputum diagnostics to match asthma/COPD patients with therapies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster presented at AAAAI 2026 annual meeting on March 1, 2026, reports ability to identify antibody drug receptors in sputum.","Technology detected receptors for dupilumab and benralizumab, leading asthma/COPD therapies.","Company leveraging CyPath® Lung flow cytometry and AI platform for new asthma/COPD diagnostic tests.","CyPath® Lung commercial test has 92% sensitivity, 87% specificity for early-stage lung cancer detection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107633,"accession_number":"0001493152-26-007965","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces validation study with Brooke Army Medical Center for CyPath Lung test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study with BAMC to validate CyPath Lung on sputum obtained by tracheal/bronchial suctioning for early lung cancer detection.","Enrolling 30-50 patients; results expected by mid-2026.","Potential to expand sample collection options; currently patients collect sputum at home.","U.S. bronchoscopy procedures ~500,000 annually; market valued at $700-920M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107632,"accession_number":"0001493152-26-007464","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies releases case study showing CyPath Lung helps avoid biopsy in elderly patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung test was negative for a 79-year-old woman with suspicious LDCT finding, supporting surveillance over invasive biopsy.","Repeat CT scan in October 2025 showed nodule resolved, validating the conservative management decision.","Test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.","Case study highlights CyPath Lung's role in reducing unnecessary procedures in high-risk patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107631,"accession_number":"0001493152-26-007139","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies publishes CyPath Lung case study showing 92% sensitivity in small nodules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.","Case study: 59-year-old with 30-year smoking history, COPD, multiple Lung-RADS 3 nodules; negative CyPath result.","Negative result allowed continued CT surveillance; follow-up CT showed stable nodules, avoiding invasive procedures.","Company markets test as LDT; case study reinforces clinical utility for reducing anxiety and supporting treatment decisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107630,"accession_number":"0001493152-26-006004","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"bioAffinity posts new presentation materials; no details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company published new investor presentation on its website as of February 10, 2026.","Presentation materials intended for use in management discussions about operations and performance.","No specific financial or operational updates from the presentation are included in this 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107629,"accession_number":"0001493152-26-005796","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity appoints three lung cancer specialists to Medical and Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Ost (MD Anderson), Daniel Sterman (NYU Langone) and J. Scott Ferguson (Univ. of Wisconsin) joined the advisory board.","Advisory board provides guidance on clinical priorities and broader adoption of CyPath® Lung diagnostic test.","CyPath® Lung is a noninvasive test for early lung cancer detection with 92% sensitivity and 87% specificity in clinical studies.","New appointees join current members including David Hill, Neil Alexis, Sheila Habib, and Sandeep Bansal.","Company says appointments align with its focus on integrating CyPath® Lung into standard care for indeterminate pulmonary nodules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107628,"accession_number":"0001493152-26-005109","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"bioAffinity Technologies sets 2026 Annual Meeting for April 30; proposal deadline Feb 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting scheduled for April 30, 2026 at company's principal executive offices in San Antonio, TX.","Special Meeting of Stockholders (Dec 19, 2025) adjourned without business due to lack of quorum; proposals will be included in Annual Meeting.","Stockholder proposals or director nominations must be received by Feb 14, 2026, ten days after this announcement.","Details of proposals and proxy statement to be filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107627,"accession_number":"0001493152-26-000814","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies maintains CAP accreditation for lab subsidiary PPLS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Precision Pathology Laboratory Services (PPLS) passed rigorous CAP on-site inspection, retaining gold-standard accreditation.","Reaffirms quality, accuracy, and patient safety for CyPath Lung test and all lab services lines.","CEO states ongoing CAP accreditation supports value proposition with physicians, health systems, and partners.","Lung cancer diagnostics market projected to grow from $4.8B (2024) to $10.4B by 2034 at 8.1% CAGR.","CyPath Lung test demonstrates 92% sensitivity, 87% specificity, 88% accuracy in detecting early-stage lung cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124009,"accession_number":"0001493152-25-028809","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dr. Joyce transfers Village Oaks Pathology equity to Dr. Humphreys; new succession agreement executed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Joyce (77) informed Company of desire to transfer 100% stock of Village Oaks Pathology to Dr. Humphreys; not due to disagreement.","On Dec 22, 2025, Village Oaks Pathology, PPLS, and Dr. Humphreys entered a Succession Agreement restricting disposal of equity.","Agreement provides for automatic transfer of equity to a successor upon death, disability, retirement, incompetence, or failure to meet eligibility requirements.","Dr. Humphreys must use commercially reasonable efforts to preserve Village Oaks Pathology's operations, contracts, and licenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124008,"accession_number":"0001493152-25-028584","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"bioAffinity adjourns special meeting due to lack of quorum; reconvenes Jan 19, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting of stockholders adjourned Dec 19, 2025 because insufficient shares present for quorum.","Adjourned meeting will reconvene Jan 19, 2026 at 8:00 a.m. Central Time.","Record date remains Nov 4, 2025; proposals voted on unchanged.","Stockholders who already voted need not take action; proxies remain valid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124007,"accession_number":"0001493152-25-025893","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity to present CyPath Lung data showing Stage 1A detection in challenging cases at ACS NLCRT Dec 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung identified Stage 1A lung cancer in three patients with atypical presentations.","Poster session at American Cancer Society National Lung Cancer Roundtable on Dec 8, 2025, 2:35-3:15 p.m. ET.","Chief Medical Officer Gordon Downie presenting cases from Titus Regional Hospital Lung Nodule Clinic.","Test uses flow cytometry and AI on sputum; prior study showed 92% sensitivity and 87% specificity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124006,"accession_number":"0001493152-25-022604","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.","CyPath Lung testing revenue increased 122% YoY; test volumes up 97% in first nine months of 2025.","Net loss $5.1M ($4.74 per share) compared to $2.0M loss ($4.84 per share) in Q3 2024, driven by change in fair value of warrants.","Raised $10.4M gross proceeds from equity transactions; cash and equivalents increased to $7.7M from $1.1M at year-end 2024.","Appointed Roberto Rios and John J. Oppenheimer to board; regained full Nasdaq compliance for listing of BIAF and BIAFW."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":4569146.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124005,"accession_number":"0001493152-25-020816","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.","Medical practices with multiple CyPath orders rose 106% QoQ in Q3 and 67% in Oct vs YTD monthly avg.","CyPath Lung noninvasive sputum test uses AI/flow cytometry; clinical study showed 92% sensitivity, 87% specificity.","CEO Maria Zannes cites growing physician trust and successful outreach to pulmonologists, health systems, VA centers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124004,"accession_number":"0001493152-25-019829","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces Australian patent acceptance for lung health platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IP Australia accepted patent application AU 2019253111 for a flow cytometry-based platform to detect multiple lung diseases.","The patent covers methods using fluorescent probes to identify cellular signatures of lung disease in sputum samples.","Patent will be automatically issued in three months unless a third party files an opposition.","Company now holds 18 awarded and 33 pending patents globally, including in the U.S., China, Japan, and Europe.","The technology underpins CyPath® Lung, the company's noninvasive test for early-stage lung cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124003,"accession_number":"0001493152-25-018643","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies to present CyPath® Lung processing research at CHEST 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Poster presented Oct 22, 2025 by Rossella Titone, PhD at poster board #4324.","Study evaluates sputum storage and shipping temperature effects on flow cytometry outcomes.","Research supports protocols for home-collected sputum samples with two-day result turnaround.","CyPath® Lung previously reported 92% sensitivity, 87% specificity, 88% accuracy in early-stage lung cancer detection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124002,"accession_number":"0001493152-25-018267","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity receives US patent allowance for AI-driven lung cancer diagnostic","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["USPTO allowed patent covering AI-built algorithm and flow cytometry platform for CyPath Lung test.","Patent titled 'Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning'.","CyPath Lung uses TCPP porphyrin and AI to detect lung cancer in sputum; clinical results: 92% sensitivity, 87% specificity, 88% accuracy.","Global patent estate now includes 18 awarded and 33 pending patents across 12 countries.","Diagnostic aims to detect early-stage lung cancer (Stage 1A) noninvasively, potentially curative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124001,"accession_number":"0001493152-25-018093","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.","Subject to one-year Mandatory Panel Monitor; if equity rule breached, no additional time to regain compliance but hearing available.","Common stock (BIAF) and warrants (BIAFW) continue trading on Nasdaq Capital Market.","CEO Maria Zannes: regaining compliance allows focus on CyPath Lung test and building shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124000,"accession_number":"0001493152-25-017627","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies closes $1.8M registered direct offering of 720K shares at $2.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 720,000 shares of common stock at $2.50/share; gross proceeds of ~$1.8M before fees.","Net proceeds to fund working capital, support growing sales of CyPath® Lung, and general corporate purposes.","Officers and directors subject to 60-day lock-up; company restricted from further equity issuance until Nov 14, 2025.","WallachBeth Capital acted as sole placement agent; received 8.0% cash fee plus up to $75K expenses.","Offering closed on October 9, 2025; shares sold under effective shelf registration statement on Form S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123999,"accession_number":"0001493152-25-017328","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity reports Q3 CyPath® Lung test sales up 95% QoQ, 97% YTD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath® Lung test sales in Q3 2025 increased 95% over Q2 2025; nine-month sales up 97% vs same period 2024.","Growth driven by adoption at Veterans’ hospitals and market expansion in the mid-Atlantic region.","New patients using CyPath® Lung rose 77% in Q3; patient compliance for at-home sample collection improved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140680,"accession_number":"0001493152-25-016366","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"bioAffinity closes $4.8M public offering; Nasdaq compliance extension received","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.8M from sale of 1,921,761 shares/pre-funded warrants at $2.50/$2.493 per unit.","After closing and warrant exercises, common shares outstanding total 3,100,402.","1-for-30 reverse stock split effective Sept 19; eliminated ~$4M in derivative liabilities.","Company believes it regained compliance with Nasdaq minimum bid price and equity requirements; extension granted to Oct 2.","Warrant amendments and exercises contributed ~$2.8M equity and ~$1.3M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140679,"accession_number":"0001493152-25-013892","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces 1-for-30 reverse stock split effective Sept 19, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-30 reverse stock split effective at open of trading on Nasdaq on September 19, 2025.","Post-split outstanding shares approximately 1,338,029; fractional shares paid in cash.","Reverse split intended to bring Company into compliance with Nasdaq minimum bid price requirement.","Proportionate adjustments to exercise prices and shares underlying stock options and warrants.","CUSIP for common stock changes to 09076W307; trading symbol BIAF unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140678,"accession_number":"0001641172-25-026971","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies case study shows CyPath Lung detects cancer in ground-glass nodules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Case study: 66-year-old former smoker with 13mm ground-glass nodule; CyPath Lung returned 'likely malignant' result.","Robotic bronchoscopy confirmed lung cancer after positive CyPath result; patient referred for surgical treatment.","Current guidelines recommend 2-5 years watchful waiting; CyPath may reduce diagnostic delay and uncertainty.","Company issued press release on September 9, 2025 highlighting real-world clinical utility of CyPath Lung."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140677,"accession_number":"0001641172-25-026758","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"bioAffinity prepares presentation materials for H.C. Wainwright conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation materials furnished for use at H.C. Wainwright 27th Annual Global Investment Conference (Sep 8-10, 2025).","No financial or operational details included in the filing; exhibit text not provided.","Materials are furnished under Item 7.01 and not deemed filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140676,"accession_number":"0001641172-25-026403","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"U.S. Medicine Magazine features CyPath Lung, citing potential $895M savings and 92% sensitivity","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CyPath Lung featured in U.S. Medicine pulmonary issue, highlighting improved lung cancer detection for veterans.","Economic modeling shows up to $895M savings for private payers, $379M for Medicare if used in 2022 standard of care.","Clinical performance: 92% sensitivity, 87% specificity, 88% accuracy in nodules ≤20 mm.","Case studies report Stage 1A detection when PET/CT, serum markers, and risk models failed.","Study authored by BAMC and VA pulmonologists, supporting integration into VA standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140675,"accession_number":"0001641172-25-026168","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"bioAffinity amends warrants to raise floor price from $0.10 to $0.15, reducing potential May warrant shares by ~17.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased floor price in May 2025 and August 2025 warrants from $0.10 to $0.15, effective August 12, 2025.","May 2025 warrant shares issuable reduced from 53,377,497 to 35,584,997.","August 2025 warrants remain subject to shareholder approval.","No other terms were changed beyond the floor price adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140674,"accession_number":"0001641172-25-024614","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies appoints Roberto Rios and John Oppenheimer to board; Gary Rubin resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roberto Rios (CPA) and John J. Oppenheimer (M.D.) appointed to Board, each term expiring at 2026 annual meeting.","Gary Rubin resigned from Board and Nominating Committee effective Aug. 12, 2025, not due to any disagreement.","Rios appointed Chair of Audit Committee and member of Compensation Committee; Oppenheimer on Nominating and Governance Committee.","Jamie Platt appointed to Audit Committee and as Chair of Nominating and Governance Committee; Robert Anderson on Compensation Committee.","New directors bring expertise in finance (Rios) and clinical respiratory research (Oppenheimer) to support CyPath Lung sales and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140673,"accession_number":"0001641172-25-024172","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"bioAffinity closes $1.45M capital raise and reclassifies warrants adding $2.8M to equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 990 Series B Preferred shares convertible into ~4.3M common at $0.23/sh and warrants for ~6.7M shares at $0.352/sh, gross proceeds ~$1.2M.","Warrant inducement: existing warrants exercised at reduced $0.23/sh for $253K cash; new warrants for 1.43M shares at $0.352/sh pending stockholder approval.","Warrant amendment reclassifies May 2025 warrants from liability to equity, increasing stockholders' equity by ~$2.8M.","Anti-dilution adjustment on May 2025 warrants reduces exercise price to $0.23/sh and increases shares issuable by ~8M.","Authorized common shares increased from 100M to 350M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140672,"accession_number":"0001641172-25-024036","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity Q2 2025 net loss $4.1M; CyPath Lung revenue up 62% H1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.3M in Q2 2025 vs $2.4M in Q2 2024, reflecting discontinuation of unprofitable pathology services.","CyPath Lung testing revenue grew 62% YTD to $323K; monthly tests set records in June and July.","Net loss $4.1M ($0.17/share) vs $2.1M ($0.19/share) in Q2 2024, increase driven by non-cash warrant remeasurement and offering costs.","Cash $0.8M at June 30, 2025; completed $3.25M public offering in May 2025 to bolster working capital.","Appointed Dr. Gordon Downie as CMO; expanded IP portfolio with patents in US, China, Canada, Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":3123080.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140671,"accession_number":"0001641172-25-023488","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"bioAffinity receives Nasdaq delisting notice; July CyPath Lung sales up 72% over prior monthly average","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Company on Aug 7 that it failed to regain minimum bid price by Aug 6 and is ineligible for second 180-day period.","Stockholders' equity of $1,439,404 at March 31, 2025 remains below the $2.5M minimum, adding a second delisting basis.","Company intends to appeal by Aug 14, 2025; delisting scheduled for Aug 18 if appeal not filed.","July completed tests for CyPath Lung surged 72% over the average of the first six months of 2025.","Company reaffirms forecast of 3X year-over-year revenue for CyPath Lung; back-to-back record months in June and July."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140670,"accession_number":"0001641172-25-021677","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CyPath® Lung detects Stage 1A lung cancer missed by standard tests in case study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung identified Stage 1A invasive mucinous adenocarcinoma in a 62-year-old female with heavy smoking history and COPD.","Previous PET scan showed low uptake; blood-based risk test indicated only 11% malignancy risk; serial LDCTs appeared stable.","CyPath test result of 0.56 classified as 'likely malignancy', prompting surgical wedge resection in June 2025.","Final pathology confirmed Stage 1A cancer; patient quit smoking in March 2025; surgery enabled curative intervention.","Test uses AI and flow cytometry on sputum to detect cancer cells; previously showed 92% sensitivity in clinical study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140669,"accession_number":"0001641172-25-021012","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"bioAffinity shareholders approve reverse stock split, share increase, and anti-dilution warrant adjustments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven proposals passed at July 25, 2025 Annual Meeting.","Reverse stock split approved; no adjournment needed as all measures passed.","Share increase amendment approved, allowing more authorized shares.","Issuance of up to 2.93M shares upon warrant exercise approved.","Anti-dilution provision approved, allowing up to 49.9M additional shares upon warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140668,"accession_number":"0001641172-25-020705","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies: CyPath® Lung detects Stage 1A tumor missed by PET scan, bronchoscopies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath® Lung identified a Stage 1A neuroendocrine tumor after PET scan, bronchoscopies and serum tumor marker suggested non-cancerous inflammation.","Patient was an 80-year-old former smoker with a 13mm nodule; CyPath® Lung returned a score of 0.72 indicating likely cancer.","Based on CyPath® Lung result, patient underwent robotic wedge resection in June 2025; pathology confirmed Stage 1A neuroendocrine tumor.","CyPath® Lung has 92% sensitivity, 87% specificity and 88% accuracy for lung cancer in high-risk patients with small nodules (<20mm)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140667,"accession_number":"0001641172-25-020581","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies receives Canadian patent allowance for CyPath Lung diagnostic","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Canadian Patent Office allowed patent (No. 3,136,245) for method using flow cytometry and TCPP to detect lung cancer in sputum.","Patent protects CyPath Lung test, which showed 92% sensitivity, 87% specificity, 88% accuracy in clinical studies.","Patent follows recent Chinese patent award; expands international IP portfolio.","Lung cancer is leading cause of cancer death in Canada; ~31,000 diagnosed in 2024.","CEO Maria Zannes says patent validates diagnostic platform and supports shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140666,"accession_number":"0001641172-25-019714","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity receives China patent allowance for lung cancer diagnostic using flow cytometry","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CNIPA allowed patent 'System and Method for Determining Lung Health' covering use of antibodies and TCPP porphyrin to label sputum cells for lung cancer detection via flow cytometry.","China has ~300M smokers (nearly 1/3 of world total) and estimated 1.06M new lung cancer cases in 2022; patent positions CyPath Lung for market expansion.","CyPath Lung commercial test showed 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in high-risk patients with nodules <20mm; 80% of Stage 1 cancers detected.","Patent complements bioAffinity's global patent estate including U.S., Japan, Australia, Mexico, Canada, EU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158404,"accession_number":"0001641172-25-013021","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"bioAffinity receives Nasdaq delisting notice; equity of $1.44M below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $1,439,404 as of March 31, 2025, well below the $2,500,000 minimum.","Company must submit a compliance plan by July 11, 2025 (45 days) to regain compliance.","If plan accepted, Nasdaq may grant up to 180-day extension from May 27, 2025.","Trading continues on Nasdaq Capital Market under BIAF and BIAFW symbols pending resolution.","This notice is separate from prior bid price deficiency notice received February 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158403,"accession_number":"0001641172-25-012411","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"bioAffinity Technologies enters $5.8M ATM equity sales agreement with WallachBeth Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM agreement with WallachBeth Capital to sell up to $5,801,000 of common stock.","WallachBeth will receive 3.0% commission on gross proceeds of shares sold.","Company sets parameters for sales; no obligation to sell any shares.","Agreement can be terminated on 10 days' notice by either party.","Shares offered under existing S-3 shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-05-27T23:59:59+00:00|158403"}